Skip to main content
Equibles
NVAX logo

NVAX

Novavax Inc
$9.33 -0.07 (-0.74%) At close · Jul 10
Market Cap
$1.53B
Shares
164,438,119

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$9.33 Open$9.38 Day$8.94–9.40 52W$6.20–11.97 Avg vol 30d4.5M Short int45.8M · 27.9% float · 9.3d Short vol42% Last earningsMay 6, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026 Est · unconfirmed · in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 6, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 15 · calm Equity put/call 0.55
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +9%
      above
      Price vs 50-day avg +1%
      above
      RSI (14) 51
      neutral
      MACD trend Positive
      52-week position 54%
      mid-range
      Momentum
      relative strength
      Very Strong
      1-month return +9%
      trailing
      6-month return +20%
      trailing
      YTD return +39%
      this year
      Relative strength +11%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $9 › 200d $9 — 50d above 200d
      Institutional flow Distributing
      11 of 259 funds reported for Jun 30 · net -365.6K sh shares
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      27.86% of float · ▲ +1.5% MoM · 9.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      259 holders — near 3-yr high, broad support
      Squeeze score 78
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +65%
      Y/Y
      EPS growth +310%
      Y/Y
      Balance sheet $3.6M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 69%
      annualized · 1-yr
      Max drawdown −36%
      past year
      ATR 6.0%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record
      Latest guidance · from the 8-K filed May 6, 2026
      Non-GAAP combined R&D and Selling, General and Administrative (S · full year 2028 Non-GAAP Initiated $150M – $200M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +9% Bullish
      Price vs 50-day avg
      +1% Bullish
      RSI (14)
      51 Neutral
      MACD trend
      Positive Bullish
      52-week position
      54% Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $9 › 200d $9 — 50d above 200d
      Institutional flow Distributing
      11 of 259 funds reported for Jun 30 · net -365.6K sh shares
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      27.86% of float · ▲ +1.5% MoM · 9.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      259 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $6 Now $9 · 54% 52-wk high $12
      vs 200-day avg +9% vs 50-day avg +1%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      R21/Matrix-M malaria vaccine doses sold since launch 30M since launch in mid-2024 —
      Sanofi milestones earned $225M FY2025 —
      Takeda market share with Nuvaxovid in Japan 12% FY2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      NVAX
      Novavax Inc
      this stock
      		$1.53B +38.8% +64.7% — 27.9%
      ONC
      BeOne Medicines Ltd.
      		 $431.70B -1.7% +22179.2% 878.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $123.19B +7.1% +46.2% 28.8 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $69.67B -13.8% +20.8% 16.2 3.3%
      ARGX
      Argenx SE
      		 $54.85B +4.4% — — 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      257
      % held
      72.7%
      Reported
      11 of 259
      Top holder
      SHAH CAPITAL MANAGEMENT
      Held Float
      View
      Held by Funds
      Fund positions
      164
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      45.8M
      Days to cover
      9.3d
      Change
      +696.6K sh
      View
      Short Volume
      Short vol %
      42%
      As of
      Jul 10, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      18.0K
      Value
      $162.6K
      As of
      Jun 12, 2026
      View
      Off-Exchange
      Off-exchange %
      48.6%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Pat Roberts
      Amount
      $1.0K–$15.0K
      Traded
      Oct 13, 2020
      View
      Financials
      Financials
      Revenue (FY)
      $1.1B
      Net income (FY)
      $440.3M
      EPS diluted
      $2.58
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      9
      View
      Proposed Sales
      Value
      $75.9K
      Shares
      10.0K
      Filed
      May 19, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 4, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      NVAX -4.2% +9.0% +19.9% -1.0% +38.8%
      SPY +1.4% +4.1% +9.1% +1.1% +10.7%
      vs SPY -5.6% +4.9% +10.9% -2.1% +28.1%
      Key facts CIK 1000694 CUSIP 670002401 13F (30d) 17 filings 11 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)